CompoAtlas

Ashwagandha KSM-66 & Lion's Mane

Food supplement declared in France, decision dated 12 November 2026

Ashwagandha KSM-66 & Lion's Mane (New Leaf Products) is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition.

Brand
New Leaf Products
Food business operator placing the product on the market
JDS Distribution BV
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Directions for use
Prendre 2 gélules par jour avec un grand verre d'eau.
Intended populations
Men and women aged 18 and over
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Heart problems, Liver problems, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Autre : énergie, Mémoire, Humeur, Concentration

Declaration 382175, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Withania somnifera (L.) DunalRacineExtrait sec hydroalcoolique116.7 mg
Hericium erinaceusCarpophoreExtrait sec hydroalcoolique40 mg
Piper nigrum L.FruitExtrait sec hydroalcoolique0.2 mg

Additives

E464

Other ingredients

farine de riz

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne sont pas un substitut à une alimentation variée et équilibrée et à un mode de vie sain. Réservé aux adultes. Déconseillé aux personnes de moins de 18 ans. Déconseillé aux femmes enceintes et allaitantes. Déconseillé aux personnes atteintes de troubles endocriniens (particulièrement les dysthyroïdies et l’hyperandrogénie). Déconseillé aux personnes atteintes de troubles hépatiques ou cardiaques. Déconseillé en cas de conduite de véhicules ou l’utilisation de machines et/ou en association avec des substances à action dépressive du système nerveux central. Si vous avez un problème de santé ou si vous prenez des médicaments sur ordonnance, demandez l'avis de votre médecin avant de l'utiliser. Ne pas utiliser si le sceau de sécurité est ouvert ou endommagé. Tenir hors de portée des jeunes enfants.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Withania somnifera (L.) Dunal
    Read the warning, when it applies and the studies cited

    ASHWAGANDHA - WITHANIA SOMNIFERA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).

    Sources cited by Health Canada (3)
    • McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
    • Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.

    When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).

    Sources cited by Health Canada (3)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
    • Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.

    Health Canada monograph dated 28 February 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : New Leaf Products

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line